Global Pancreatic Amylase Reagent Market By Type (R1: 5x20ml, R2: 1x25ml, R1: 5x80ml, R2: 1x100ml, R1: 1x800ml, R2: 1x200ml, R1: 1x1000ml, R2: 1x250ml), By Indication (Pancreatic Disorders, Cancer, Cystic fibrosis), By End-User (Hospitals, Specialty Clinics, Diagnostic Centers, Research Centers), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2021-2031

Pancreatic Amylase Reagent Market Overview

The enzyme pancreatic amylase is produced in the pancreatic tissue and aids in the digestion of starch from meals. The pancreatic amylase reagent assay was used to determine the amount of pancreatic amylase in plasma and serum. The colorimetric approach is used in this pancreatic amylase reagent assay. A pancreatic amylase reagent is typically used to identify acute and chronic pancreatitis.

Perforated ulcers, gall bladder illnesses, mumps, and ectopic pregnancy are also diagnosed using a pancreatic amylase reagent. A pancreatic amylase reagent is used to activate the two monoclonal antibodies in serum or plasma, which raises the sample’s light absorbance. The wavelength of absorbed light aids in the identification of pancreatic amylase in the sample. The normal pancreatic amylase level in the body is between 19 to 86 units per liter (U/L).

However, to get a good result, the right pancreatic amylase regent should be used throughout the test. Sodium phosphate, monobasic buffer, sodium chloride, potato starch, sodium hydroxide, potassium sodium tartrate, and 3,5-Dinitrosalicylic acid are all included in the pancreatic amylase regent kit.

Detailed Segmentation –

Based on Type:

• R1: 5x20ml, R2: 1x25ml
• R1: 5x80ml, R2: 1x100ml
• R1: 1x800ml, R2: 1x200ml
• R1: 1x1000ml, R2: 1x250ml

Based on Indication:

• Pancreatic Disorders
• Cancer
• Cystic fibrosis

Based on End-User:

• Hospitals
• Specialty Clinics
• Diagnostic Centers
• Research Centers

Based on Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Market Dynamics –

Drivers for the Global Pancreatic Amylase Reagent Market:

This market is projected to expand as the use of amylase testing of the pancreas and salivary glands becomes more common for effective evaluation. Furthermore, acute illnesses such as ectopic pregnancy rupture, chronic or alcoholic pancreatitis, and digestive conditions can be effectively examined utilizing amylase testing, which is expected to propel this market forward.

Restraints Global Pancreatic Amylase Reagent Market:

Alternative diagnosis methods for pancreatic testing, such as CT scans and endoscopies, may result in slower market growth for pancreatic amylase reagents. The general lack of public awareness concerning cystic fibrosis and pancreatic cancer could explain the existing state of stagnation in the pancreatic amylase reagent market.

Opportunities for the Global Pancreatic Amylase Reagent Market:

Owing to the ease of use of testing by blood or urine samples, as well as the increasing prevalence of chronic illnesses such as pancreatitis among the smoking population, this market is predicted to create various revenue growth opportunities for this market

Trends for the Global Pancreatic Amylase Reagent Market:

People suffering from cystic fibrosis in developing nations where the facilities to cater to this disorder may not be as proficient. Countries such as India, South Africa, and Brazil would generate significant revenue for the pancreatic amylase reagent market as a direct result of this.

Owing to this, a majority of visits to various medical facilities for the diagnosis of various ailments is expected to have a profound influence on the healthcare sector, in turn, boosting the revenue growth trajectory of the pancreatic amylase reagent market.

Competitive Landscape –

• DIALAB GmbH
• DiaSys Diagnostic Systems
• Randox Laboratories Ltd.
• Abbott Laboratories S.R.O.
• Biocompare
• VitroScient
• Merck KGaA
• Biosystems S.A.

Recent Developments of Major Players –

• Merck has bought 29 companies, with 16 of them in the last five years. Private equity firms made a total of eight purchases. It has also sold off seven assets. Merck’s greatest acquisition to date was Schering-Plough, which it paid US$41.1 billion for, in 2009. Its largest publicly announced transaction was the US$4.0 billion sales of Merial to Sanofi S.A. in 2009. Merck has made acquisitions in ten different US states and seven international countries. Life science (90%) and information technology(4%) are the two most important sectors for the company.
• Danaher has completed three purchases and three investments: Aldevron (Jun 2021), Precision Nanosystems (Jun 2021), and GE Healthcare Life Sciences (Apr 2020). The acquisitions have cost the corporation more than US$51.04 billion. Danaher has made investments in a variety of industries, including Life Sciences Platforms and Tools, Diagnostics (by Technology), Dentistry, etc.

For the Pancreatic Amylase Reagent Market research study, the following years have been considered to estimate the market size: